Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome

• Main Authors: Teri J Mauch (Author), Michael R Chladek (Author), Spero Cataland (Author), Shruti Chaturvedi (Author), Bradley P Dixon (Author), Katherine Garlo (Author), Anuja Java (Author), Jorge Leguizamo (Author), Lucy Lloyd-Price (Author), Tan P Pham (Author), Tara Symonds (Author), Ioannis Tomazos (Author), Yan Wang (Author)
• Format: Book
• Published: Becaris Publishing Limited, 2023-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Aim: Ravulizumab and eculizumab are complement C5 inhibitors approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Ravulizumab requires less frequent infusions than eculizumab, which may reduce treatment burden. This study investigated patients' treatment preferences and the...